27th week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150182501 | Compositions - The invention provides a colon cleansing solution comprising:
| 2015-07-02 |
20150182502 | COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING N-METHYLENENAPHTHO[2,1-b]FURAN-2-CARBOHYDRAZIDE DERIVATIVES AS AN ACTIVE INGREDIENT - The present invention relates to ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate, the novel mitosis inhibitor. The said ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate not only induces apoptosis by inhibiting tubulin polymerization in the course of mitosis but also displays an excellent anticancer effect in the multi-drug resistant cancer cells, so that it can be effectively used for the treatment of cell proliferative disease including various cancers. | 2015-07-02 |
20150182503 | MINERALOCORTICOID RECEPTOR ANTAGONISTS - The present invention is directed to compounds of the Formula I: as well as pharmaceutically acceptable salts thereof, that may be useful for treating aldosterone-mediated diseases. The invention furthermore relates to specific diastereomers and enantiomers of the compounds, to processes for preparing compounds of the Formula I, to their potential use for the therapy and prophylaxis of the above-mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I. | 2015-07-02 |
20150182504 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR - Provided herein are methods and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation and/or a PI3K gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist. | 2015-07-02 |
20150182505 | SOLID FORMS OF (S)-2-METHOXY-3--PROPIONIC ACID AND OF SALTS THEREOF - The present invention relates to solid forms of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid, and of salts of (S)-2-methoxy-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl}-propionic acid. | 2015-07-02 |
20150182506 | Modulators of Aldehyde Dehydrogenase and Methods of Use Thereof - The present disclosure provides compounds that function as modulators of aldehyde dehydrogenase (ALDH) enzymatic activity, as well as compositions and formulations comprising the compounds. The present disclosure provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 2015-07-02 |
20150182507 | IMIDAZOPYRIDINE DERIVATIVES USEFUL IN TREATING DIABETES - The present invention relates to imidazopyridine derivatives of the following general formula I: | 2015-07-02 |
20150182508 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYMORPHIC FORMS ALPHA, BETA, AND GAMMA OF RIFAXIMIN - Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin α and rifaximin β, and a poorly crystalline form referred to as rifaximin γ, useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention. | 2015-07-02 |
20150182509 | TETRACYCLIC COMPOUNDS - This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic [4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. | 2015-07-02 |
20150182510 | Systems, Methods, Techniques, and Compounds in Research and Treatment of Portal Hypertension and other Conditions - Methods and compounds for research and treatment of portal hypertension. The use of racemic or non-racemic mixtures of furopyridine isomers to stimulate eNOS function in sinusoidal endothelial cells and to increase NO production in both normal sinusoidal endothelial cells and injured endothelial cells. | 2015-07-02 |
20150182511 | MODULATORS OF ALDEHYDE DEHYDROGENASE ACTIVITY AND METHODS OF USE THEREOF - The present invention provides compounds that function as modulators of aldehyde dehydrogenase activity; and pharmaceutical compositions comprising the compounds. The present invention provides therapeutic methods involving administering a subject compound, or a subject pharmaceutical composition. | 2015-07-02 |
20150182512 | METHODS AND COMPOSITIONS FOR TREATING INFECTIONS COMPRISING A LOCAL ANESTHETIC - The present invention is directed to a drug depot useful for reducing, preventing or treating an infection in a patient in need of such treatment. The drug depot includes a polymer and a therapeutically effective amount of a local anesthetic or pharmaceutically acceptable salt thereof. The drug depot is administered at a site to reduce, prevent or treat an infection. The drug depot is capable of releasing (i) a bolus dose of the local anesthetic or pharmaceutically acceptable salt thereof at the site and (ii) a sustained release dose of an effective amount of the local anesthetic or pharmaceutically acceptable salt thereof over a period of at least 4 days at the site. | 2015-07-02 |
20150182513 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents - The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors, and more specifically their use to treat bacterial infections. | 2015-07-02 |
20150182514 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE - The present invention provides, among other things, compounds represented by the general Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, R | 2015-07-02 |
20150182515 | METHODS FOR TREATING OBESITY AND DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL - The disclosure relates to methods for treating hyperlipidemia in a mammal. The present disclosure also relates to methods for treating and/or controlling obesity in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, AEGR-733 and implitapide) and a DGAT inhibitor (for example, JTT-553 or PF-04415060). Co-administration of the MTP inhibitor with the DGAT inhibitor produces a therapeutic benefit, for example, a reduction in the concentration of cholesterol and/or triglycerides in the blood stream, but with fewer or reduced side effects than when higher dosages of the MTP inhibitor are used during monotherapy to provide the same or similar therapeutic benefit. | 2015-07-02 |
20150182516 | DRUG DELIVERY SYSTEMS AND METHODS FOR TREATMENT OF BLADDER DYSFUNCTION OR DISORDER USING TROSPIUM - Methods, devices, and medicaments that include trospium are provided for use in the treatment of bladder dysfunction by locally administering the trospium into the bladder to achieve a sustained concentration of trospium in urine in the bladder sufficient to produce a therapeutic concentration of trospium in bladder tissue. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days. | 2015-07-02 |
20150182517 | Pharmaceutical Compositions of (R)-1-(2,2-Difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6- -fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and Administration Thereof - A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed. | 2015-07-02 |
20150182518 | CANCER CELL INHIBITORY DRUG AND CANCER STEM-CELL DETECTION PROBE - An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. The present invention provides a cancer cell inhibitory drug comprising at least one compound represented by general formula (1) as an active ingredient. | 2015-07-02 |
20150182519 | Methods For Enhancing The Release And Absorption of Water Insoluble Active Agents - Methods for enhancing the release and/or absorption of poorly water soluble active agents are described herein. The method involves dissolving, melting, or suspending a poorly water soluble active agent in one or more molten fatty acids, conjugated fatty acids, (semi-) solid surfactants of high HLB value, and/or hydrophilic polymers. The molten active agent mixture is then suspended and homogenized in a hydrophilic or lipophilic carrier to form microparticles suspended in the hydrophilic or lipophilic carrier. The particles suspended in the hydrophilic or lipophilic carrier can be encapsulated in a hard or soft gelatin or non-gelatin capsule. It is believed that the microparticles produced by the method described above will exhibit enhanced dissolution profiles. In vitro release studies of formulations containing cilostazol and fenofibrate showed 100% dissolution of cilostazol in 15 minutes and over 90% dissolution of fenofibrate in 35 minutes. | 2015-07-02 |
20150182520 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 2015-07-02 |
20150182521 | METHODS FOR TREATING PANCREATIC CANCER USING COMBINATION THERAPIES COMPRISING LIPOSOMAL IRINOTECAN - Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin. | 2015-07-02 |
20150182523 | COMPOSITIONS COMPRISING APOMORPHINE AND ORGANIC ACIDS AND USES THEREOF - The present invention provides stable liquid or semi-solid pharmaceutical compositions of apomorphine, more particularly composition comprising apomorphine and an organic acid, which are useful in treatment of neurological or movement diseases or disorders, e.g., Parkinson's disease, or conditions associated therewith. | 2015-07-02 |
20150182524 | COMPOSITIONS AND METHODS FOR WEIGHT LOSS IN AT RISK PATIENT POPULATIONS - The present disclosure relates to compositions, kits, uses, systems and methods related to naltrexone plus bupropion for treating an overweight or obese subject at increased risk of adverse cardiovascular outcomes. Preferably, the subject has had type-two diabetes for a period of less than 6 years or is a current smoker, optionally that does not have type-two diabetes. | 2015-07-02 |
20150182525 | 4-Amino-5-Fluoro-3-[6-(4-Methylpiperazin-1-YL)-1H-Benzimidazol-2-YL]-1H-Qu- inolin-2-one for use in the Treatment of Adenoid Cystic Carcinoma - The present invention describes a method of reducing solid tumors in a subject having an adenoid cystic carcinoma comprising administering a therapeutically effective amount of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-yl]-1H-quinolin-2-one or a pharmaceutically acceptable salt thereof. | 2015-07-02 |
20150182526 | PYRIDO[2,3-B]PYRAZIN-8-SUBSTITUTED COMPOUNDS AND THEIR USE - The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF) activity, to inhibit receptor tyrosine kinase (RTK) activity, to inhibit cell proliferation, and in the treatment of diseases and disorders that are ameliorated by the inhibition of RAF, RTK, etc., proliferative disorders such as cancer (e.g., colorectal cancer, melanoma), etc. | 2015-07-02 |
20150182527 | COMPOSITIONS, DEVICES AND METHODS OF TREATING INFECTIONS - One aspect provides a composition including a quaternary ammonium salt and an azole. The azole and the quaternary ammonium salt can be present in proportions providing a synergistic effect against a fungal organism. In one embodiment, the composition also includes a pharmaceutically acceptable carrier. Another aspect provides implantable medical devices containing a composition including a quaternary ammonium salt and an azole. In certain embodiments, the combination is present in an elutable form. Another aspect provides methods of treating a human or veterinary patient for an infection including administrating a composition including a quaternary ammonium salt and an azole. | 2015-07-02 |
20150182528 | THIOCHROMENE DERIVATIVES AS HIF HYDROXYLASE INHIBITORS - The present invention relates to novel compounds, methods, and compositions capable of decreasing HIF hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (HIF). | 2015-07-02 |
20150182529 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF - Described herein are compounds that are androgen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such androgen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon androgen receptors. | 2015-07-02 |
20150182530 | TREATMENT OF DRY EYE - The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter “BTK”) inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds. | 2015-07-02 |
20150182531 | Novel Protein Kinase B Inhibitors - 060 - The invention relates to a novel group of compounds of Formula (I) or salts thereof: | 2015-07-02 |
20150182532 | COMPOSITIONS AND METHODS OF TREATING CELL PROLIFERATION DISORDERS - The invention relates to compounds and methods for treating cell proliferation disorders. | 2015-07-02 |
20150182533 | 5-HT3 RECEPTOR ANTAGONISTS - The present invention provides a method of treating nicotine addiction comprising administering a 5-HT3 receptor antagonists of Formula (I): | 2015-07-02 |
20150182534 | OXATHIAZINE DERIVATIVES AS ANTIBACTERIAL AND ANTICANCER AGENTS - New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. | 2015-07-02 |
20150182535 | Antimicrobial Composition for the Treatment of Methicillin-resistant Staphylococcus aureus - Antibiotic resistance in bacteria may be an inherent trait or may be acquired by mutation. Bacteria that are resistant to antibiotics have become a serious public health threat. For example, approximately 1% of the population in the world has methicillin-resistant | 2015-07-02 |
20150182536 | TUMESCENT ANTIBIOTIC SOLUTION - Disclosed herein are solutions and kits for tumescent antibiotic delivery. Embodiments of the solution comprise an antibiotic component, an anesthetic component and a vasoconstrictor component. In addition, a method of use is disclosed comprising subcutaneous delivery of the solution. The disclosed solution, kit and method of subcutaneous delivery can be used for a variety of surgical procedures including liposuction, mastectomy and others. The tumescent antibiotic solution can be administered to a patient in situations where establishing IV access is difficult, impossible, or undesirable. A variety of delivery methods appropriate for surgical settings, as well as for use by first responders are likewise disclosed. | 2015-07-02 |
20150182537 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 2015-07-02 |
20150182538 | SILICONE-BASED COMPOSITION FOR SKIN TREATMENT - The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethicone, and C30-45 alkyl cetearyl dimethicone crosspolymer, and include several active ingredients, such as glucocorticoids, antihistamines, and nerve depressants. The silicone-based gel may include a combination of fluticasone, loratadine, and gabapentin. The concentrations of fluticasone and loratadine may be relatively low, while that of gabapentin moderately high. The silicone-based gel may also have one or more local anesthetics, such as prilocaine and/or lidocaine. The silicone-based gel may include additional active ingredients, such as NSAIDs, anticonvulsants, antidepressants, muscle relaxants, and/or other active ingredients. | 2015-07-02 |
20150182539 | PREGNANCY HORMONE COMBINATION FOR TREATMENT OF AUTOIMMUNE DISEASES - The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis. | 2015-07-02 |
20150182540 | DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY - A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6β,7β;15β;16β-dimethylene-3-oxo-17α-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form. | 2015-07-02 |
20150182541 | SHELL-AND-CORE DOSAGE FORM APPROACHING ZERO-ORDER DRUG RELEASE - Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode. | 2015-07-02 |
20150182542 | DIETARY AND NUTRITIONAL COMPOSITIONS AND METHODS OF USE - A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine. | 2015-07-02 |
20150182543 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 2015-07-02 |
20150182544 | Modified Saponins for the Treatment of Fungal Infections - Methods of treating a fungal infection in a subject, the method comprising administering to the subject a modified saponin. | 2015-07-02 |
20150182545 | MATERIALS AND METHODS FOR TREATING DISEASES CAUSED BY GENETIC DISORDERS USING AMINOGLYCOSIDES AND DERIVATIVES THEREOF WHICH EXHIBIT LOW NEPHROTOXICITY - Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health. | 2015-07-02 |
20150182546 | THERAPEUTIC AGENT FOR ENHANCING MITOCHONDRIAL FUNCTION - Methods are provided for enhancing metabolic performance at the mitochondrial level. The methods include administering an adenylosuccinate in amounts sufficient to treat, in diseased tissue, symptoms and pathologies resulting from dysfunctional metabolism, i.e. subnormal production of adenosine triphosphate (ATP) and to enhance normal mitochondrial respiration in healthy tissue. | 2015-07-02 |
20150182547 | SALTS OF HIV INHIBITOR COMPOUNDS - The invention is related to salts of anti-viral compounds, compositions containing such salts, and therapeutic methods that include the administration of such salts, as well as to process and intermediates useful for preparing such salts. | 2015-07-02 |
20150182548 | CYANOCOBALAMIN, METHYLCOBALAMIN, AND/OR ADENOSYLCOBALAMIN TO HELP MAINTAIN A PAIN-FREE HEAD AND PAIN-FREE BODY AND PROVIDE DEFENSE AGAINST HEADACHES AND BODY PAIN - The current invention discloses novel approaches to help individuals defend against headaches and body pains with orally-delivered cyanocobalamin, methylcobalamin, adenosylcobalamin, and combinations thereof. Original clinical research conducted by the inventor on almost 2,000 humans yielded surprising and unexpected results showing differences in the frequency and severity of pains in the head and the body favoring cyanocobalamin patients over placebo. In one FDA-approved Phase III study on 1,551 patients, 4.4 percent of headaches and body pains were rated as “Severe” in the cyanocobalamin, group versus 11.5 percent in the placebo group. Once inside the body, cyanocobalamin is converted to methylcobalamin and adenosylcobalamin, but not to hydroxocobalamin. The current invention provides the patient's mitochondria with sufficient concentrations of essential micronutrients to survive, increase in number and manufacture the chemical energy (ATP) that is required to prevent the brief vasoconstriction followed by vasodilation associated with headache and body pain. | 2015-07-02 |
20150182549 | METHOD FOR ENZYMATIC GLYCOSYLATION OF OLIGOSACCHARIDES FROM MAMMALIAN ANIMAL MILK - A method for modifying galactosyl disaccharides in order to enhance their bifidogenic effect, comprising reacting at least one glycosyl donor with a precursor galactosyl disaccharide or a mixture of precursor galactosyl disaccharides using enzyme catalysis, compounds obtainable by said method and the use of such compounds in consumable products. | 2015-07-02 |
20150182550 | INHIBITORS OF THE INTERACTION OF THE SIGMA-1 RECEPTOR WITH hERG FOR USE IN THE TREATMENT OF CANCER - A method of treating cancer is described. The method includes administering to a person in need thereof an effective amount of a ligand selected from the group consisting of shRNA, igmesine, and (+) pentazocine, wherein the ligand modulates a channel macrocomplex comprising a sigma-1 receptor and an ion channel. | 2015-07-02 |
20150182551 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING LOW MOLECULAR WEIGHT HYALURONIC ACID AND ASTAXANTHIN - A dietary supplement composition is formulated in a therapeutic amount to treat and alleviate symptoms of joint pain. The composition includes pro-inflammatory low molecular weight microbial fermented sodium hyaluronate fragments having a molecular weight of 0.5 to 300 kilodaltons (kDa) and astaxanthin in an oral dosage form. The astaxanthin may be derived from a natural or synthetic ester or synthetic diol. The composition may include a mixture of cartilage and salt and boron. | 2015-07-02 |
20150182552 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING PHOSPHOLIPIDS AND ASTAXANTHIN - A dietary supplement composition and associated method of use has the composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a person having joint pain. The composition includes astaxanthin and microbial fermented, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan). The composition also includes at least one of a phospholipid, glycolipid, and sphingolipid. It is formulated into an oral dosage form and the astaxanthin is 0.1 to 15 percent by weight of the at least one phospholipid, glycolipid, and sphingolipid. | 2015-07-02 |
20150182553 | USE OF POLYMER D-LACTIC ACID (PDLA) TO TREAT MALARIA - The reaction of L-lactate and polymer D-lactic acid (PDLA) spontaneously and rapidly forms a stereocomplex. This versatile chemical reaction can disrupt glycolysis, the predominate form of ATP production in many disease states, and may have many uses including the treatment of malaria. PDLA can sequester lactate in the vicinity of hypermetabolic activity such as that associated with | 2015-07-02 |
20150182554 | SURFACE ACTIVE AGENT COMPOSITIONS AND METHODS FOR ENHANCING OXYGENATION, REDUCING BACTERIA AND IMPROVING WOUND HEALING AT A SITE OF TREATMENT - This present invention relates generally to the use of novel formulations comprising a surface active polymer to enhance oxygenation in skin and other soft tissue. The present invention also discloses formulations that can be used to improve clinical outlook and reducing bacteria. Methods of making and using the same are also disclosed. | 2015-07-02 |
20150182555 | PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHATE BINDING POLYMER - The present invention relates to a fast dissolving tablet comprising a therapeutically effective amount of a phosphate binding polymer, such as sevelamer or pharmaceutically acceptable salt or derivative thereof, that exhibit limited swelling in the oral cavity, has pleasant taste and mouth feel, high phosphate binding capacity with fast binding kinetics and require limited amount of water intake. A process for the preparation thereof is disclosed. | 2015-07-02 |
20150182556 | HYDROPHILIC PHOSPHATE GROUP CONTAINING DEHYDRATED PARTIALLY PURIFIED BONE REPLACEMENT MATERIAL - The invention provides: —A hydrophilic dehydrated partially purified bone replacement material of natural origin, wherein substantially all non-collagenous organic material is removed while inorganic, porous osseous structure and collagenous structure of natural bone are substantially preserved, characterized in that the bone replacement material contains 0.05 to 1.5 w/w % of at least one of a saccharide or a sugar alcohol, and 0.7 to 5.6 w/w % of a phosphate group selected from the group consisting of phosphate HPO4 | 2015-07-02 |
20150182557 | NOVEL FERMENTED MILK PRODUCT AND METHOD FOR PRODUCING THE SAME - The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23. | 2015-07-02 |
20150182558 | METHOD AND APPARATUS FOR HARVESTING, CREATING AND IMPLANTING A FIBRIN CLOT BIOMATERIAL - A composite biomaterial comprising at least one blood component and adipose-derived stem cells wherein the at least one blood component is bonded to the adipose-derived stem cells as the at least one blood component coagulates. | 2015-07-02 |
20150182559 | Compositions for Repair of Defects in Tissues, and Methods of Making the Same - Tissue repair compositions, particularly bone repair compositions, containing (a) bone fragments and (b) homogenized connective tissue, and methods for making the same are provided. Some of the inventive tissue repair compositions contain a radioprotectant. The compositions can be used in the form of an injectable gel, an injectable paste, a paste, a putty, or a rehydratable freeze-dried form. Kits for using such tissue repair compositions are also provided. | 2015-07-02 |
20150182560 | TISSUE ENGINEERING OF LUNG - The present invention relates to compositions comprising a decellularized tissue. The present invention also provides an engineered three dimensional lung tissue exhibiting characteristics of a natural lung tissue. The engineered tissue is useful for the study of lung developmental biology and pathology as well as drug discovery. | 2015-07-02 |
20150182561 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING PHOSPHOLIPIDS AND ROE EXTRACT - A dietary supplement composition and associated method has its composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain in a person having joint pain. The composition includes astaxanthin, low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of 0.5 to 300 kilodaltons (kDa), and a phospholipid rich egg roe extract having phospholipid bound EPA and DHA admixed with seed and/or fish oil having an ALA to LA ratio of 1:1 to 6:1 and in an oral dosage form. | 2015-07-02 |
20150182562 | TREATING A PARASITIC DISEASE WITH A WHOLE, LEECH SALIVA EXTRACT - Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined, whole saliva in the regurgitation of the cooled leech. The methods can include revitalizing the leech by warming it at a temperature ranging from about 5° C. to about 40° C. Stable, lyophilized, whole-saliva extracts of a leech are also provided, the extract having a stable activity when stored for use at a temperature below about −20° C., the extract maintaining at least 70% of the activity for at least 6 months. The extracts can be used to treat solid tumors, treat liquid tumors, treat diabetes, treat a viral disease, treat a parasitic disease, treat an antibacterial disease, or serve as an anti-oxidant. | 2015-07-02 |
20150182563 | CO-PROCESSING METHODS FOR HONEY NASAL RINSE PRODUCTION - Novel nasal rinse compositions are disclosed. The nasal rinse comprises a dried particulate composed of honey and a carrier. The composition may be a co-processed composition wherein the honey and carrier are combined while the honey is in liquid form and processed together to produce the dried particulate. Methods for producing the nasal rinse compositions are also provided, as well as methods of use of the nasal rinse compositions for the prevention or treatment of nasal infection, rhinitis, or sinusitis. | 2015-07-02 |
20150182564 | PROBIOTIC FOR AMELIORATION OF COCCIDIOSIS VACCINE REACTION - Methods for improving the health of agricultural poultry are provided. For example, methods including selecting specific bacteria to form a probiotic for the administration with coccidiosis vaccines for the reduction of adverse effects associated with the coccidiosis vaccines are disclosed. In accordance with various aspects of the present disclosure, a bacterial isolate, probiotic and or treatment may be obtained by novel screening methods resulting in products that are advantageously administered with or about the same time as a coccidiosis vaccine. | 2015-07-02 |
20150182565 | LACTIC ACID AND OTHER PROBIOTIC BACTERIA TO REDUCE PATHOGENS IN LYMPH NODES AND OTHER LYMPHATIC TISSUES OF LIVESTOCK ANIMALS - The present invention includes compositions and methods for eliminating or reducing microbial contamination in lymph nodes that enter the food supply from livestock comprising: identifying an animal in need of eliminating or reducing microbial contamination in non-gut associated lymph nodes that enter the food supply, and providing the animal with an effective amount of a lactic acid bacteria or probiotic bacterial sufficient to reduce or eliminate the microbial contamination in non-gut associated lymph nodes. | 2015-07-02 |
20150182566 | LACTIC ACID BACTERIUM-CONTAINING PREPARATION - An object of the present invention is to provide a useful composition that contains a highly safe lactic acid bacterium or a component derived from this lactic acid bacterium. The present invention relates to a composition comprising at least one lactic acid bacterium selected from the group consisting of | 2015-07-02 |
20150182567 | LACTOBACILLUS SUPPLEMENT FOR ALLEVIATING TYPE 1 DIABETES | 2015-07-02 |
20150182568 | SACCHAROMYCES CEREVISIAE YEAST FOR PREVENTING AND/OR TREATING VAGINAL MYCOSES - The present invention relates to the | 2015-07-02 |
20150182569 | Neuroprotective Natural Extract from Passion Fruit - Methods for the treatment and prevention of neural cell and neuro-pathological disorders are provided, comprising contacting the neural cells, or administering to a subject in need thereof, botanical raw material (BRM) or an extract obtainable from passion fruits. Compositions, as well as a nutraceutical composition comprising the same are also provided. | 2015-07-02 |
20150182570 | COMPOSITION HAVING A. paniculata FOR WOUND HEALING AND SKIN WHITENING, AND METHOD BY USING THE SAME - The present invention provides a pharmaceutical composition for wound healing and/or skin whitening. The pharmaceutical composition comprises active ingredient of | 2015-07-02 |
20150182571 | COMPOSITION COMPRISING DENDROPANAX MORBIFERAEXTRACT OR COMPOUND DERIVED THEREFROM AS ACTIVE INGREDIENT FOR PREVENTING AND TREATING BENIGN PROSTATIC HYPERPLASIA - Provided is a use of | 2015-07-02 |
20150182572 | PLANT EXTRACT AND THE PROCESS FOR TREATING HEPATIC FIBROSIS AND LIVER CANCER - An extract of | 2015-07-02 |
20150182573 | PLANT EXTRACTS MADE OF SIDERITIS AND USE THEREOF TO BOOST COGNITIVE PERFORMANCE - The invention relates to aboveground plant parts of | 2015-07-02 |
20150182574 | COMPOSITIONS AND METHODS FOR ENHANCING MOBILIZATION AND PROLIFERATION OF BLASTOMERE-LIKE STEM CELLS - The present invention provides a method of using mobilization agents to enhance stem cell trafficking in a subject, including very small embryonic-like (VSEL) stem cells. In one embodiment, a blended composition of algae, fruits, mushrooms, microorganisms, maternal fluids, and extracts thereof are used to promote trafficking of stem cells, resulting in migration of the stem cells to specific sites of maintenance and repair within tissues and/or organs. | 2015-07-02 |
20150182575 | USE OF PHY906 AS TREATMENT FOR INFLAMMATORY BOWEL DISEASE AND/OR IRRITABLE BOWEL SYNDROME - The present invention includes a method of using PHY906 for treating a bowel disorder including inflammatory bowel disease and irritable bowel syndrome. Particularly, the present invention provides a multiple symptoms treatment for the bowel disorder. | 2015-07-02 |
20150182576 | MULTI-CAROTENOIDS COMPOSITIONS AND USES THEREFOR - Methods for ameliorating the effects of benign prostate hyperplasia (BPH)-related lower urinary tract symptoms (LUTS) in men, comprising orally administering an effective amount of multi-carotenoids compositions. Multi-carotenoids composition for oral administration comprising about 71% by weight, of a tomato extract containing therein about 2% to 10% by weight of lycopene, about 0.25% to 2% by weight of phytoene, and about 0.2% to 2% by weight of phytofluene, and about 29% by weight, of a suitable encapsulating matrix. A suitable encapsulating matrix is an edible oil exemplified by soya oil, pumpkin seed oil, grape-seed oil and the like. The tomato extract may additionally comprise one or more of at least one carotene selected from the group comprising β-carotene, γ-carotene, and δ-carotene, a phytosterol, a tocopheral and a phospholipid. Use of multi-carotenoids compositions for the treatment of urinary tract malfunctions including benign prostate hyperplasia and lower urinary tract symptoms. | 2015-07-02 |
20150182577 | Composition For Improving Macular Pigment Density And Preventing Or Treating Age-Related Macular Degeneration - The present invention provides a composition for improving macular pigment optical density and preventing or treating age-related macular optical degeneration. The composition comprises lutein, zeaxanthin and tea extracts, wherein the weight ratio of zeaxanthin to lutein is more than or equal to 1. The composition may prevent formation of choroidal neovascularization to achieve effects on comprehensively preventing or treating age-related macular optical degeneration (AMD). | 2015-07-02 |
20150182578 | GEL FOR TOPICAL APPLICATION OF CLOVE ESSENTIAL OIL WITH BROAD SPECTRUM ANTI-INFLAMMATORY ACTION AND METHOD OF PREPARING SAME - A gel for topical application of clove essential oil with broad spectrum anti-inflammatory and analgesic action disclosed containing by weight of the total composition of: 30.0% of deionized water; 0.3% of acrylates/C10-30 alkyl acrylate crosspolymer; 0.1% of glycerin; 0.2% 0.2% of triethanolamine, 0.1% of tocopherol acetate; 0.5% of fragrance; 5% of clove essential oil; 2% of black pepper essential oil; 61.4% of isopropyl alcohol SDA; at least 0.1% of aloe barbadensis leaf extract; 0.2% of parabens mixture; the parabens mixture further comprising of 3% propylparaben, 11% methylparaben, and 30% diazolidinyl; and at least 0.1% (w) of ethylenediamine tetraacetic acid; and the method of preparation of said gel therein. | 2015-07-02 |
20150182579 | Dietary Fibre for Use in the Treatment of a Gastro-Intestinal Side-Effect of a Nutrition or Medicament - The invention relates to a dietary fibre for use in delaying or otherwise reducing a sating effect of a medical nutrition or of a medicament, wherein the medical nutrition or medicament is for oral or gastro-enteric administration by a human. The invention further relates to a method for prophylactically or therapeutically treating a human in need thereof, the treatment comprising administering an effective amount of a dietary fibre, in combination with a pharmaceutical composition or a nutrition as defined in any of the preceding claims, thereby reducing a sating effect of the pharmaceutical composition or the nutrition. The invention further relates to products suitable for use in such a method. | 2015-07-02 |
20150182580 | Collagen Peptide Composition Production Method, DPP-4 Inhibitor, and Antihyperglycemic Agent - Provided are methods of producing a novel collagen peptide composition, and a DPP-4 inhibitor and antihyperglycemics that comprise the above-mentioned collagen peptide composition. Ginger rhizome-derived enzymes are added to and break down a collagen and/or gelatin solution to generate peptide compositions comprising peptides represented by X-Hyp-Gly (wherein X represents an amino acid residue other than Gly, Hyp, and Pro). The thus obtained collagen peptide composition has a high DPP-4 inhibitory activity and an excellent antihyperglycemic effect. | 2015-07-02 |
20150182581 | PEPTIDE INHIBITORS AS NOVEL ANTI-HIV THERAPEUTICS - The present invention relates to synthetic peptide inhibitors (Seq ID No. 67-71) useful as anti-HIV therapeutics. The invention also relates to a novel screening method for screening anti-HIV molecules. The present invention relates to a synthetic peptide useful as anti-HIV therapeutic. The invention also relates to a novel screening method for screening of anti-HIV therapeutics. In particular, the present invention relates to reporter gene constructs for the detection of the HIV Nef and host ASK1 protein interaction. Furthermore, the invention relates to a functional interaction for Nef-ASK1 proteins prepared in a recombinant manner, a method for identifying of Nef-ASK1 interaction which causes activation of pathway to activate apoptosis presumably causing immune evasion for HIV in infected cells. The reporter gene construct according to the present invention, after it had been introduced into cells, in the presence of HIV Nef and host ASK1 proteins result in the expression of reporter luciferase protein which may be used for quantitative/qualitative interaction of HIV Nef and host ASK1 protein. The both interacting construct cloned in fluorescence expression vector when transfected in eukaryotic cells inhibits ASK1 mediated apoptosis and were reversed by the inhibitors. Furthermore, the invention was used to identify the inhibitor for the interaction of Nef-ASK1 in the cell. | 2015-07-02 |
20150182582 | Methods of Treating Depression and Other Related Diseases - The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist. | 2015-07-02 |
20150182583 | METHODS FOR TREATMENT AND PREVENTION OF TAUOPATHIES BY INHIBITING ENDOTHELIN RECEPTORS - Compositions and methods of treatment of tauopathies are provided. In some embodiments, an antagonist of endothclin receptor A (ETA) and endothelin receptor B (ETB) may be administered to a subject to reduce tau production or accumulation, e.g., in astrocytes. The antagonist may be a dual ETA and ETB receptor antagonist. In some aspects, methods are provided for the treatment of chemo-brain, hypoxia, brain ischemia, surgical dementia, glioblastoma, or a traumatic brain injury (TBI). | 2015-07-02 |
20150182584 | ROMIDEPSIN FORMULATIONS AND USES THEREOF - Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer. | 2015-07-02 |
20150182585 | DEACETYLASE INHIBITOR THERAPY - The present invention relates to deacetylase inhibitor (e.g., histone deacetylase inhibitor) therapies and demonstrates that individuals with low electrolyte levels may have increased susceptibility to certain unwanted side effects such as cardiac side effects. In some embodiments, the invention provides methods of administering DAC or DAC inhibitor therapy that includes electrolyte supplementation. | 2015-07-02 |
20150182586 | DAIRY FARM TEAT DIP COMPOSITIONS AND METHODS - Disclosed herein are teat dip compositions, comprising a) a fermentation derived mixture that include low molecular weight protein component; b) an emollient; c) one or more surfactants; and d) an anti-microbial agent. The disclosed methods provide for preventing milk contamination and associated bacterial infections of the teat in dairy animals, the method comprises applying to the teat of the dairy animal a composition, comprising: a) a fermentation derived mixture that include low molecular weight protein component; b) an emollient; c) one or more surfactants; and d) an anti-microbial agent, wherein the application is effective in treating mastitis of the teat, and wherein the composition is gentle on the teat tissue. | 2015-07-02 |
20150182587 | METHODS FOR TREATING REPERFUSION INJURIES - The present invention relates to treating a tissue in a mammal from the effects of reperfusion using flagellin | 2015-07-02 |
20150182588 | SYNTHETIC MEMBRANE-RECEIVER COMPLEXES - Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith. | 2015-07-02 |
20150182589 | TREATMENT OF MUSCULAR DYSTROPHIES AND RELATED DISORDERS - The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. | 2015-07-02 |
20150182590 | VESICLES COMPRISING EPIDERMAL GROWTH FACTOR AND COMPOSITIONS THEREOF - The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering. | 2015-07-02 |
20150182591 | METHOD OF TREATING HYPERGLYCEMIC DISORDERS USING APOLIPOPROTEIN AIV - Methods for treating hyperglycemia disorders in a subject in need thereof and pharmaceutical compositions for the treatment of hyperglycemia disorders are disclosed. The methods include administering an effective amount of apolipoprotein A-IV to the subject. Also disclosed are methods for substantially restoring glucose tolerance in a subject in need thereof to a normal level and methods for lowering blood glucose levels in a subject having hyperglycemic disorders, including insulin resistant disorders, such as prediabetes, metabolic syndrome, polycystic ovary disease, type A syndrome, gestational diabetes, and endocrine conditions associated with hyperglycemia, including Cushing's Disease, glucagon excess (glucagon secreting tumors) and acromegaly. | 2015-07-02 |
20150182592 | Composition Comprising At Least Two Compounds Which Induce Indolamine 2,3 - Dioxygenase (IDO), for the Treatment of an Autoimmune Disorder or Suffering from Immune Rejection of Organs - A composition and method for using a composition, the composition having at least two compounds, each of which induces indolamine | 2015-07-02 |
20150182593 | COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE - The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases. | 2015-07-02 |
20150182594 | NOVEL GLUCAGON ANALOGUES - The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 2015-07-02 |
20150182595 | Preparation Comprising Insulin, Nicotinamide and an Amino Acid - Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid. | 2015-07-02 |
20150182596 | TARGETED THERAPEUTICS - The present invention relates to compositions, methods and kits for delivery of active agents (X) to cells or tissues that express proteoglycans. More specifically, the present invention relates to conjugates comprising (HB-linker) | 2015-07-02 |
20150182597 | COMPOSITIONS COMPRISING HYALURONIC ACID AND DERMATAN SULPHATE FOR THE TREATMENT OF BEING OVERWEIGHT AND OBESITY - The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes, fatty liver or dyslipidemia or for use in reducing food intake, inducing the feeling of satiety, reducing appetite, reducing body weight, preventing weight gain, reducing body fat, reducing fat formation, reducing blood cholesterol, maintaining normal blood cholesterol levels, reducing blood triglycerides, maintaining normal blood triglyceride levels or increasing insulin sensitivity. The composition can further contain collagen hydrolysate. The composition can be in the form of a pharmaceutical composition, a food, a functional food, a medical food or a food supplement. | 2015-07-02 |
20150182598 | COLLAGEN MIXTURE AND METHOD OF MAKING THE SAME - A collagen mixture having a portion of unhydrolyzed eggshell membrane collagen and Avian collagen. | 2015-07-02 |
20150182599 | SURFACTANT PROTEIN D FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH LUNG INJURY - Surfactant protein D (SP-D) is a 43-kDa member of the collectin family of collagenous lectin domain-containing proteins that is expressed in epithelial cells of the lung. Described herein are methods and compositions for the treatment of disorders associated with lung injury, including methods and compositions for the treatment of bronchopulmonary disorder (BPD) using recombinant human surfactant protein D and surfactant formulations. | 2015-07-02 |
20150182600 | METHODS OF TREATING ANEMIA AND RED BLOOD CELL DYSFUNCTION WITH LECITHIN CHOLESTEROL ACYLTRANSFERASE - Disclosed are methods for treating conditions characterized by anemia or red blood cells dysfunction by administering an agent that increases the level of endogenous LCAT or LCAT activity. Additionally disclosed are methods of treating conditions wherein red blood cells have reduced function in relation to deformability, oxygenation, increased adhesion and aggregability, reduced nitric oxide function, or decreased life-span, increased free cholesterol, or abnormal phospholipid content. Also disclosed are methods for treating conditions characterized by an abnormal concentration of free cholesterol in red blood cells and methods of normalizing the free cholesterol content of red blood cells. | 2015-07-02 |
20150182601 | COMPOSITIONS AND METHODS FOR SELECTIVELY PRODUCING SIRNA - The disclosure provided herein provides compositions and methods for producing siRNA. Also disclosed are compositions and methods for modulating the production of siRNA. Also disclosed herein are compositions and methods of treating a disease in a subject comprising administering a Dicer enzyme comprising a helicase domain or a mutated Dicer enzyme to a subject. Also disclosed herein are methods of screening for a candidate modulator that modulates siRNA production. | 2015-07-02 |